Rare disease drug R&D exchange symposium held

According to the National Medical Products Administration, the "Care First" Rare Disease Drug Research and Development Exchange Symposium was held at the Drug Evaluation Center of the National Medical Products Administration on February 28. The meeting pointed out that in recent years, the National Medical Products Administration has continuously strengthened the guarantee of rare disease drug use, played a good policy "combination punch", established and smoothed out three channels for encouraging innovation, accelerating introduction, and temporary importation, and the number and speed of the listing of rare disease drugs in China have significantly increased. By 2025, 48 rare disease drugs have been approved for marketing, allowing more patients to simultaneously enjoy international advanced treatment methods and drugs. The meeting emphasized that the resolution of problems in the rare disease field urgently requires greater institutional innovation and resource integration. The National Medical Products Administration will continue to strengthen policy supply and enhance service support in the evaluation and approval process. At the same time, it is necessary to strengthen multi-party cooperation, consolidate consensus and strength, and promote the application of new technologies and products.